All In MedTech

Device Trial Radar · NCT00578617

Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation - Pilot Trial

Last checked: Nov 20, 2026Latest source record: Jan 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

60

Actual

Start

Sep 2006

Primary completion

Feb 2009

Study completion Jun 2010

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Duke Clinical Research Institute; Abbott Medical Devices
First posted
Dec 21, 2007

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up.

Conditions

  • Atrial Fibrillation
  • Arrhythmia

Interventions

  • Rate ControlDrug

    Metoprolol 50-100mg

  • Ablation TherapyDevice

  • Rate ControlDrug

    Atenolol 50-100mg,

  • Rate controlDrug

    Propranolol 40-80mg

  • Rate controlDrug

    Acebutolol 200mg

  • Rate controlDrug

    Carvedilol 6.25mg

  • Rate ControlDrug

    Diltiazem 180-240mg

  • Rate ControlDrug

    Verapamil 180-240mg

  • Rate ControlDrug

    Digoxin 0.125mg

  • Rhythm ControlDrug

    Propafenone 450mg

  • Rhythm controlDrug

    Flecainide 200mg

  • Rhythm controlDrug

    Sotalol 240mg

  • Rhythm controlDrug

    Dofetilide 500mcg

  • Rhythm controlDrug

    Amiodarone 200mg

  • Rhythm controlDrug

    Quinidine 600-900mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Recurrence of Atrial Fibrillation by One Year Follow-upTime frame: 12 months after intervention

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Universtity of Alabama Hospital

    Birminham, Alabama

  • Good Samaritan Hospital

    Los Angeles, California

  • Loyola University

    Maywood, Illinois

7 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.